Abstract In the present study, two new series of pyrazolines (3a-h & 4a-h) were synthesized starting from p-acetamidophenol (paracetamol) and evaluated for their antibacterial, antifungal and antitubercular activities. Chalcones (2a-h) prepared by condensing 3-acetyl-4-hydroxyphenyl acetamide (1) with different aromatic aldehydes were reacted with phenyl hydrazine and isonicotinic acid hydrazide to obtain phenyl-pyrazolines (3a-h) and isoniazid-pyrazolines (4a-h), respectively. The structures of the synthesized compounds were confirmed by spectral and microanalysis studies. Newly prepared pyrazoline compounds exhibited significant antibacterial activity against the organisms Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa when compared with the standard antibiotic Ciprofloxacin. Compound 4g showed potent antibacterial activity against P. aeruginosa and S. aureus (MIC-3.12 lg/mL), however, against E. coli compound 3d, 4c, 4d, 4f & 4g were found to have an MIC of 6.25 lg/mL. Antifungal activity of compound 4d against Candida albicans and Aspergillus niger (MIC-3.12 lg/mL) was found to be better than the standard drug Ketoconazole. The results of antitubercular activity of the synthesized compounds against Mycobacterium tuberculosis H 37 Rv by the agar microdilution method are quite promising. The
Introduction
Infection diseases such as bacterial and fungal infections have been reported to increase dramatically worldwide in recent times and one of the major causes is suppressed immunity [1] . Suppression of immunity due to various reasons such as malignancy, immunosuppressive therapies, HIV-infection, surgeries, old age etc. is a plausible cause that places patients at high risk for catching microbial infections. The situation is further worsened by increasing incidence of microbial resistance to the majority of antibiotics available today. Antimicrobial resistance is a major concern and threat to the public health and warrants development of novel and effective antibiotics to combat drug resistance [2] . Currently available antifungal agents in the market are fewer in number and majority of them have potential disadvantages with regard to their toxicity, spectrum, lack of oral formulations, few drug targets, pharmacokinetics and higher cost [3] .
Tuberculosis (TB) is one of the most important chronic communicable bacterial diseases caused by Mycobacterium tuberculosis. TB is one of the major causes of morbidity and mortality throughout the world. Approximately 32% of the world's population is currently living with this infectious disease. It is a fatal disease and one of the leading causes of the death all over the world especially in the developing countries like India. It is also believed to be the leading cause of death among HIV positive peoples. Present anti-tubercular drugs are quite effective in the treatment of TB but resistance to these drugs by M. tuberculosis strains is on the rise which is a growing concern among scientific community worldwide. New antitubercular compounds/structures are urgently needed in the present situation because very few agents belonging to first line (e.g. rifabutin) or second line drugs (e.g. capreomycin, levofloxacin) have become available for the treatment of this disease since the introduction of rifampicin in 1966 [4] . To solve these issues, there is an urgent need to develop novel alternative, safe and potent drugs with a broader spectrum of antimicrobial activity [5] . Various Nitrogen containing heterocyclic compounds such as pyrazolines, pyridazinones and pyrrolones have been studied extensively for the development of pharmaceutically important antimicrobial agents. These nitrogen containing compounds have played an important role in drug discovery owing to their diverse pharmacological actions. Pyrazolines are even more special due to their marked physiological and pharmacological activity and distinct functions. Pyrazoline derivatives were reported to possess numerous prominent pharmacological activities; antimicrobial-antibacterial and antifungal [6] [7] [8] [9] , antiamoebic [10] , anti-TB [11] , anti-HIV [12] , anticancer [13] , antidepressant and anticonvulsant [14] .
The pyrazoline ring contains N-N bond linkage which is considered to be the key factor in their biological actions. Natural abundance of compounds having N-N bonds is less because these bonds are constructed with a great difficulty by living organism [15, 16] . Isoniazid is a well known pharmacologically active antitubercular compound; therefore, we thought to synthesize pyrazoline derivatives by condensing INH and p-acetamidophenol and investigate their antibacterial, antifungal and antitubercular potential.
Experimental

Measurements
All the reagents and solvents were of LR grade and were purchased locally from S.D. Fine (Mumbai, India), Merck (Mumbai, India) and CDH (New Delhi, India). Melting points were recorded in liquid paraffin bath using open end capillaries and are uncorrected. The IR spectra were recorded on a Thermo Nicolet avatar 330-FT-IR spectrophotometer using KBr pellets. Bruker spectrospin DPX-300 MHz was used to record 1 H NMR spectra of the synthesized compounds in CDCl 3 ; TMS was used as an internal standard and chemical shift values (d) are expressed as parts per million (ppm). Following abbreviations were used do describe the splitting patterns of peaks in proton NMR spectra: s-singlet; d-doublet; dd-double doublet; m-multiplet. Mass spectral data for title compounds were recorded on a JEOL JMS-D 300 instrument. Perkin-Elmer 240 analyzer was used to perform elemental analyses (C, H, N) and were found in the range of ±0.4% for each analyzed element. Progress of reactions was monitored on thin-layer chromatography (TLC) using silica gel G (Merck) as stationary phase in the solvent system-Toluene: Ethyl acetate: Formic acid (5:4:1, v/v/v); iodine chamber, and UV lamp were used for visualization of TLC spots.
Synthesis of the compounds
Synthesis of 3-acetyl-4-hydroxyphenyl acetamide (1)
A mixture of p-acetamidophenol (0.322 mol) in dry pyridine (10 mL) and acetic anhydride (5 mL) was heated on water bath for 3 h. It was cooled and poured onto crushed ice, filtered, washed with water and crystallized from acetone. The product (0.103 mol) so obtained was mixed with anhydrous AlCl 3 (3 g ) and heated in oil bath at 118°C for 2 h. After completion of reaction, the reaction mixture was decomposed with dil. HCl (4%, 25 mL) which yielded a brownish mass. It was filtered, washed with water, dried and crystallized from petroleum ether: diethyl ether mixture (1:1) to get TLC pure compound 
Synthesis of pyrazolines (3a
To an ethanolic solution of chalcones 2a-h (0.01 mol; 20 mL), hydrazine hydrate (0.02 mol; 99%) was added drop wise and the reaction mixture was refluxed for 8-10 h. After completion of the reaction, the contents were concentrated and poured onto crushed ice (approx. 100 g). Solid mass was obtained which was filtered, washed with plenty of cold water and recrystallized from ethanol to get the pure product pyrazolines 3a-h. Purity of the compound was checked on TLC plates in the solvent system-benzene: methanol (8:2). The synthesized pyrazoline bearing compounds were screened for their in vitro antibacterial activity against Staphylococcus aureus (ATCC-25923), Pseudomonas aeruginosa (ATCC-27853), and Escherichia coli (ATCC-25922) bacterial strains at a concentration of 100 lg/mL by the standard cup plate method [18] . A standard drug (Ciprofloxacin) was used for comparison. Approximately 20 mL of freshly prepared liquid agar medium was poured into each petridish and then the petridishes were dried in an incubator at 37°C for duration of 1 h. An L-shaped spreader was used to spread the standardized culture of microorganism on each petridish. Cups of approximately 6 mm diameter were made in petridishes using sterile cork borer and were labeled. A solvent control was also tested to see the effect of control on the growth of the microbes. Dimethylsulfoxide (DMSO) was used to prepare the solutions of synthesized compounds and Ciprofloxacin (100 lg/mL). The prepared solutions were added to each cup in petridishes and were kept aside in an aseptic area for 1 h to allow diffusion of the drug/sample, followed by incubation at 37°C for 24 h. The diameter of the zone of inhibition (in mm) was measured and the results are shown in Table 1 .
N-(3-(
5-(3-chlorophenyl)-1-isonicotinoyl-4,5-dihydro- 1H-pyrazol-3-yl)-4-hydroxy-phenyl)acetamide (4b
N-(3-(5-(4-chlorophenyl)-1-isonicotinoyl-4,5-dihydro-1H-pyrazol-3-yl)-4-hydroxy-phenyl)acetamide (4c
N-(3-(5-(2,4-dichlorophenyl)-1-isonicotinoyl-4,5-dihydro-1H-pyrazol-3-yl)-4-phenyl acetamide (4d
N-(4-hydroxy-3-(5-(2-hydroxyphenyl)-1-isonicotinoyl-4,5-dihydro-1H-pyrazol-3-yl) phenyl)acetamide (4e
N-(4-hydroxy-3-(1-isonicotinoyl-5-(3-methoxyphenyl)-4,5-dihydro-1H-pyrazol-3-yl)phenyl)acetamide (4h
The broth dilution technique was employed to determine the MIC of selected compounds that inhibited growth of at least one microorganism as per the standard procedure [18] .
Antifungal activity
Antifungal activity of the newly synthesized pyrazoline compounds was tested by the agar diffusion assay method against Candida albicans (ATCC-10231) and Aspergillus niger (ATCC-16404) fungal organisms [19] . Ketoconazole was used as standard drug for comparison. The Minimum inhibitory concentration (MIC) required to inhibit the growth of fungus was determined.
Antitubercular activity
The antitubercular activity of the synthesized compounds was evaluated against M. tuberculosis H 37 Rv (ATCC 27294) by the agar microdilution method where twofold dilutions of each test compound were added into 7H11 agar medium supplemented with OADC (oleic acid albumin dextrose catalase) and organism [20, 21] . Streptomycin was used as a standard drug for comparison. Growth of bacilli was observed after 30 days of incubation at 37°C and minimum inhibitory concentration (MIC) was recorded.
Results and discussion
Chemistry
The title compounds were synthesized as per the Scheme 1. Sixteen new pyrazolines analogs (3a-h and 4a-h) were synthesized from chalcones (2a-h), which in turn were prepared from p-acetamidophenol (paracetamol). The starting material, 3-acetyl-4-hydroxyphenyl acetamide (1), was prepared by heating N-(4-hydroxyphenyl) acetamide with acetic anhydride in the presence of dry pyridine followed by heating with anhydrous AlCl 3 . By using Claisen-Schmidt reaction conditions, eight chalcones (2a-h) were synthesized by condensing 3-acetyl-4-hydroxyphenyl acetamide (1) with various aromatic aldehydes in alkaline medium. These compounds gave red color with conc. H 2 SO 4 which confirmed formation of chalcone.
In general, the ) were present in reasonable intensities in the mass spectra of pyrazolines. The molecular ion peak or their fragments having chloro-substituent(s) were observed as cluster of peaks. Elemental analyses (C, H, N) were within ±0.4% of theoretical values.
Antimicrobial evaluation
The synthesized pyrazoline derivatives were evaluated for their in vitro antimicrobial activities which included antibacterial, antifungal and antitubercular activities. The inhibition of microbial growth is routinely used to demonstrate the therapeutic efficacy of any subtle change in the efficacy of antibiotic molecule.
Antibacterial and antifungal activity
Among the screened compounds for antibacterial activity, compounds 4d & 4g demonstrated the highest activity against S. aureus with MIC-3.12 lg/mL, which was better than the standard drug Ciprofloxacin (MIC-6.25 lg/mL). Compound 3d, 3g, 4c, 4f & 4h also showed good antibacterial activity against S. aureus with MIC-6.25 lg/mL, which was found to be at par with that of the standard drug. The other compounds showed low to moderate antibacterial activity against S. aureus. Against E. coli, compounds 3d, 4c, 4d, 4f & 4g showed excellent activity with MIC-6.25 lg/mL, which was found to be at par with that of the standard drug. In the case of P. aeruginosa, antibacterial activity of compound 4g was found to be better than that of the standard drug (MIC-3.12 lg/mL). Five more compounds, 3d, 3h, 4d, 4e & 4g, displayed very good antibacterial activity against P. aeruginosa with MIC-6.25 lg/mL. Rest of the compounds exhibited low to moderate activity against P. aeruginosa.
The results of antifungal activity revealed that among the screened products, compounds 4d & 4g exhibited the most potent antifungal activity against C. albicans with MIC-3.12 lg/mL, the activity was found to be better than that of the standard drug Ketoconazole (MIC-6.25 lg/mL). Compounds 3c, 4c, 4e & 4h showed very good antifungal activity against C. albicans with MIC-6.25 lg/mL and found at par with the standard. Against A. niger, antifungal activity of compound 4d (MIC-3.12 lg/mL) was found to be better than that of the standard drug Ketoconazole (MIC-6.25 lg/mL).
The comparative results of antibacterial & antifungal activities indicated that the pyrazolines with chloro, hydroxyl or nitro substituent showed good activity. Further, the pyrazolines derived from isoniazid (4a-h) were better in their antibacterial & antifungal actions than those pyrazolines derived from phenyl-hydrazine (3a-h). All pyrazolines showed a broad spectrum of activity and it was worthwhile to note that two isoniazid-pyrazolines (4d, 4g) exhibited even better antibacterial & antifungal activity than the standard drugs.
The active pyrazoline compounds such as 4d & 4g which exhibited better antibacterial and antifungal activity than the standard drugs may provide valuable lead molecule(s) for the treatment of bacterial & fungal infections. 
Antitubercular activity
The results of antitubercular activity of the titled compounds are highly encouraging and are presented in Tables 1 and 2 . Among the sixteen tested compounds, three compounds, 4c, 4d & 4g, were found to be the most active compounds with MIC of 3.12 lg/mL and were more active than standard drug Streptomycin against M. tuberculosis bacteria (MTB). Five more compounds, 3b, 3d, 3g, 4f & 4h showed excellent antitubercular activity with MIC 6.25 lg/mL and their activity was at par with that of the standard drug Among the synthesized compounds, two isoniazid-pyrazolines, N-(3- (5-(2,4-dichlorophenyl)-1-isonicotinoyl-4 ,5-dihydro-1H-pyrazol-3-yl)-4-hydroxyphenyl)acetamide (4d) and N-(4-hydroxy-3-(1-isonicotinoyl-5-(4-nitrophenyl)-4,5-dihydro-1H-pyrazol-3-yl)phenyl)acetamide (4g) emerged as lead compounds with a broad spectrum of antimicrobial & antitubercular actions.
Conclusion
In the present study, 16 new compounds belonging to two series of pyrazolines (3a-h & 4a-h) were synthesized and characterized with the help of spectral data (IR, 1 H NMR & Mass) and elemental analysis studies. The title compounds were also tested for their anticipated antibacterial, antifungal & antitubercular activities against some selected microorganisms. MIC of all the newly synthesized pyrazoline derivatives was determined by using standard methods. It was observed that among the synthesized compounds, the pyrazolines derived from isoniazid (4a-h) were better in their antimicrobial & antitubercular action than those pyrazolines derived from phenyl-hydrazine (3a-h). Two isoniazid-pyrazolines namely, N-(3-(5-(2,4-dichlorophenyl)-1-isonicotinoyl-4,5-dihydro-1H-pyrazol-3-yl)-4-hydroxyphenyl) acetamide (4d) and N-(4-hydroxy-3-(1-isonicotinoyl-5-(4-nitrophenyl)-4,5-dihydro-1H-pyrazol-3-yl) phenyl) acetamide (4g) emerged as lead compounds with a broad spectrum of antimicrobial and antitubercular actions. These compounds could be further derivatizated to obtain specific and highly potent antimicrobial and/or antitubercular agents. Further research work to study their structure activity relationship and mechanism of actions is currently under progress in our lab.
